

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

Alaa Ahmed Fouad Abd El Monam ¹, Mohamed Shehta Tawfik ², Dalal El-Sayed Mohammed Soud ³,
Ezzat El- Shabrawi Galhom⁴

1 Assistant Lecturer of Anesthesia, Intensive Care & Pain Management, Faculty of Medicine, Zagazig University. Egypt

2 Professor of Anesthesia, Intensive Care & Pain Management, Faculty of Medicine, Zagazig University. Egypt

3 Professor of Anesthesia, Intensive Care & Pain Management, Faculty of Medicine, Zagazig University. Egypt

4 Lecturer of Anesthesia, Intensive Care & Pain Management, Faculty of Medicine, Zagazig University. Egypt

Corresponding Author: Alaa Ahmed Fouad Abd El Monam

Mail: alaaafouad7070@gmail.com

ABSTRACT

Background: The global rise in obesity has led to an increasing number of bariatric surgeries, with sleeve gastrectomy emerging as a leading procedure for significant weight loss and metabolic improvement. Postoperative pain management in these patients is especially challenging due to high rates of comorbidities—most notably obstructive sleep apnea and other respiratory disorders—which increase the risk of perioperative respiratory complications. Traditionally, opioids have been the cornerstone of analgesia in surgical patients. However, their known adverse effects on respiratory function, including respiratory depression, hypoventilation, and exacerbation of sleep-disordered breathing, are particularly problematic in the bariatric population, often necessitating intensive care unit (ICU) monitoring and prolonging recovery.

The development and implementation of opioid-free analgesia protocols have garnered significant interest as strategies to minimize opioid-related respiratory risks. These protocols utilize regional anesthesia, non-opioid systemic analgesics, and adjuvant agents to maintain effective pain control while avoiding the deleterious effects of opioids on respiratory physiology. Several studies suggest that opioid-free approaches may reduce postoperative respiratory events, support earlier extubation, lower rates of ICU admission and readmission, and decrease the overall burden on critical care resources. This review critically examines the impact of opioid versus opioid-free analgesia on respiratory and ICU outcomes in patients undergoing sleeve gastrectomy. Key areas addressed include the mechanisms and incidence of opioid-induced respiratory depression, comparative effectiveness of analgesic strategies on postoperative ventilation and extubation, the relationship between analgesic protocols and ICU length of stay, and the influence on sedation, delirium, and patient safety. By synthesizing current evidence, this review aims to inform best practices in perioperative pain management for bariatric surgery patients at high risk for respiratory compromise, identify remaining gaps in the literature, and provide recommendations for optimizing postoperative care in the ICU setting. Ultimately, the findings support a multidisciplinary approach to pain management that prioritizes both efficacy and respiratory safety in this vulnerable patient group.

Keywords: Opioid-Free Analgesia, Postoperative, Sleeve Gastrectomy

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

INTRODUCTION

The exponential increase in obesity worldwide has made bariatric surgery, particularly sleeve gastrectomy, an essential therapeutic intervention for sustainable weight reduction and the management of obesity-related comorbidities. While advances in surgical technique and perioperative care have improved outcomes, optimal postoperative pain management remains a significant challenge, especially for patients at high risk of respiratory compromise. This population frequently presents with obstructive sleep apnea, chronic hypoventilation, and decreased pulmonary reserves, conditions that heighten susceptibility to respiratory complications during the perioperative period and often require planned or unplanned admission to the intensive care unit (ICU).[1,2].

Opioids, despite their efficacy in controlling postoperative pain, are associated with substantial risks in bariatric patients, most notably respiratory depression, which can delay extubation, increase the need for mechanical ventilation, and contribute to ICU morbidity. The perioperative use of opioids in these patients not only increases the likelihood of hypoxemic episodes but also exacerbates pre-existing sleep-disordered breathing. These challenges have prompted growing interest in opioid-free analgesia protocols, which aim to provide adequate pain relief while minimizing respiratory side effects.[1,2].

Despite accumulating evidence in support of opioid-sparing strategies, direct comparisons of opioid versus opioid-free protocols on respiratory and ICU outcomes in sleeve gastrectomy patients remain limited, and existing studies often vary in design, patient populations, and outcome measures. As such, there is a critical need to consolidate current knowledge, evaluate the strengths and limitations of available evidence, and guide clinicians in implementing safe, effective pain management strategies for high-risk bariatric patients.[1,2].

The aim of this review is to compare the effects of opioid and opioid-free analgesia protocols on postoperative respiratory and ICU-specific outcomes in patients undergoing sleeve gastrectomy. By focusing on key domains such as respiratory depression, mechanical ventilation, sedation, delirium, and ICU resource utilization, this review seeks to clarify best practices and highlight opportunities for further research in the perioperative management of this challenging patient cohort.

Obese patients exhibit distinct respiratory physiological changes that complicate perioperative care. Increased adiposity in the thoracic and abdominal regions impairs diaphragmatic movement, reduces lung compliance, and decreases functional residual capacity. These alterations predispose bariatric patients to hypoxemia, atelectasis, and rapid desaturation during anesthesia and recovery. Moreover, a high prevalence of obstructive sleep apnea and obesity hypoventilation syndrome in this population further elevates the risk of perioperative respiratory complications, making them particularly vulnerable to the depressant effects of anesthetic agents and opioids [1,2].

Additionally, the presence of metabolic syndrome, chronic inflammation, and cardiovascular dysfunction often seen in bariatric patients may exacerbate perioperative respiratory instability. Sleep-disordered breathing not only increases baseline oxygen requirements but also heightens the risk of airway obstruction and apneic episodes during sedation and in the postoperative period. Consequently, even modest doses of opioids or sedatives can tip the balance toward critical respiratory compromise, necessitating heightened vigilance and frequently, postoperative ICU admission for monitoring and support [3,4].

Analgesics in the Perioperative Management of Sleeve Gastrectomy Patients

The management of perioperative pain in sleeve gastrectomy patients has evolved significantly over the past decade, driven by the unique challenges presented by the bariatric population. Effective analgesia not only improves patient comfort but also enhances recovery, reduces opioid-related complications, and supports early mobilization after surgery [1].

The Rationale for Multimodal Analgesia

Given the increased risk of respiratory depression in obese patients, especially those with obstructive sleep apnea (OSA), reliance on high-dose opioids is discouraged. Multimodal analgesia—using a combination of drugs acting through different mechanisms—has become the gold standard to optimize pain control while reducing opioid exposure [2].

Opioid Analgesics: Fundamental Principles

Opioid analgesics remain a cornerstone for managing moderate to severe perioperative pain. However, their use in bariatric patients is tempered by the potential for respiratory compromise and adverse effects, necessitating judicious selection and careful

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

monitoring [3].

Pharmacology of FentanylFentanyl is a synthetic phenylpiperidine opioid that exerts potent analgesic effects via mu-opioid agonism. It is 50 to 100 times more potent than morphine, providing rapid and effective pain relief during anesthesia induction and surgical procedures [4].

Fentanyl Pharmacokinetics and Administration

Due to its high lipid solubility, fentanyl is rapidly absorbed and distributed within the central nervous system, making it suitable for intravenous, transdermal, or transmucosal administration. In sleeve gastrectomy, intravenous dosing is most common due to its quick onset and controllable duration [5].

Clinical Dosing in Bariatric Patients

Obesity can alter fentanyl's pharmacokinetics, prompting the use of dosing strategies based on ideal rather than actual body weight. This minimizes the risks of excessive sedation and prolonged respiratory depression postoperatively [6].

Adverse Effects and Safety Considerations

While fentanyl is effective for acute pain, it can cause adverse effects such as bradycardia, hypotension, constipation, nausea, and the risk of respiratory depression. Muscle rigidity and rare allergic reactions may also occur, highlighting the need for vigilant monitoring [7].

Toxicity and Special Issues

Overdose can lead to life-threatening apnea and cardiac arrest, particularly when combined with other central nervous system depressants. Chronic fentanyl exposure is associated with tolerance, physical dependence, and endocrine dysfunctions such as hypogonadism [8].

Dexmedetomidine: Overview and Rationale

Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, offers anxiolysis, sedation, and analgesia without significant respiratory depression. This makes it a valuable adjunct in the management of bariatric patients at high risk for airway compromise [9].

Pharmacokinetics and Metabolism of Dexmedetomidine

Following intravenous administration, dexmedetomidine exhibits rapid distribution and a terminal elimination half-life of about two hours. It undergoes extensive hepatic metabolism, and dose adjustments may be needed for patients with liver impairment [10].

Pharmacodynamics and Mechanism of Action

Dexmedetomidine's activation of alpha-2 receptors in the locus coeruleus and spinal cord reduces norepinephrine release, producing sedative and analgesic effects. Its sympatholytic properties contribute to intraoperative hemodynamic stability [11].

Clinical Applications in Sleeve Gastrectomy

Dexmedetomidine is frequently used intraoperatively for its opioid-sparing properties, reducing both intraoperative opioid requirements and postoperative pain scores. It is also effective in minimizing emergence agitation and shivering [12].

Routes and Dosing

Intravenous infusion is the primary route, typically with a loading dose followed by continuous infusion. Other administration routes, such as intranasal or buccal, are less common but may be used in specific clinical scenarios [13].

Adverse Effects and Precautions

The principal adverse effects of dexmedetomidine are bradycardia and hypotension, which may be profound in hypovolemic or elderly patients. Careful titration and monitoring are essential to avoid hemodynamic instability [14].

Ketamine: Mechanistic Insights

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

Ketamine, a phencyclidine derivative, is a dissociative anesthetic with strong analgesic properties. It acts mainly by noncompetitive antagonism of NMDA receptors, but also interacts with opioid, serotonergic, and dopaminergic systems [15].

Pharmacokinetics of Ketamine

Ketamine is rapidly absorbed when given intravenously or intramuscularly, with an elimination half-life of about 2–4 hours. Its active metabolite, norketamine, also contributes to its analgesic effects [16].

Clinical Advantages in Bariatric Surgery

Low-dose ketamine is effective for reducing postoperative opioid requirements, preserving respiratory function, and providing hemodynamic stability—key benefits in morbidly obese patients with OSA undergoing sleeve gastrectomy [17].

Adverse and Psychoactive Effects

While ketamine is generally well tolerated, it may induce psychotomimetic symptoms such as hallucinations and dissociation, particularly at higher doses. Nausea, increased salivation, and occasional cardiovascular stimulation are also observed [18].

Paracetamol (Acetaminophen): Central Role

Paracetamol is a first-line non-opioid analgesic that plays a critical role in multimodal protocols. Its favorable safety profile and central action make it especially useful for bariatric patients [19].

Mechanism of Analgesia

The exact mechanism remains uncertain, but is believed to involve central cyclooxygenase inhibition (COX-3), serotonergic pathway modulation, and endocannabinoid system activation, contributing to both analgesic and antipyretic effects [20].

Dosing and Routes in Perioperative Care

Paracetamol is administered orally, intravenously, or rectally. The IV route is preferred perioperatively, especially in NPO patients or when rapid analgesia is required [21].

Adverse Effects and Toxicity

While rare, paracetamol toxicity is a major concern, particularly hepatotoxicity following overdose or in patients with preexisting liver disease. Allergic reactions and, less commonly, renal dysfunction may also occur [22].

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ketorolac

Ketorolac, a potent NSAID, is valued for its strong analgesic effect without the sedative or respiratory depressive properties of opioids, making it suitable for opioid-free anesthesia strategies [23].

Mechanism and Clinical Use of Ketorolac

By inhibiting COX-1 and COX-2 enzymes, ketorolac decreases prostaglandin synthesis, providing both peripheral and central analgesia. Its use must be balanced against the risk of gastrointestinal bleeding and renal impairment, especially after major surgery [24].

Routes, Dosing, and Adverse Effects

Ketorolac may be administered intravenously, intramuscularly, or orally. Doses are limited to short durations due to risks of GI ulceration, renal dysfunction, and impaired platelet aggregation, which can increase bleeding risk in surgical patients [25].

Dexamethasone in Perioperative Pain and Nausea Control

Dexamethasone, a long-acting corticosteroid, is widely employed to reduce postoperative nausea and vomiting, as well as to augment analgesia by decreasing inflammatory mediators [26].

Mechanisms and Clinical Considerations

Dexamethasone acts through inhibition of phospholipase A2 and suppression of pro-inflammatory cytokines. While beneficial for pain and nausea control, it can cause hyperglycemia, delayed wound healing, and immunosuppression, especially in diabetic and obese patients [27].

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

Safety and Adverse Effects

Short-term perioperative use is generally safe, but caution is warranted in patients with diabetes, infection, or a history of peptic ulcer disease. Chronic use can lead to Cushingoid features, adrenal insufficiency, and mood disturbances [28].

Clinical Relevance of Analgesic Strategies in Sleeve Gastrectomy

The choice of analgesics must be individualized, accounting for each patient's comorbidities, surgical risk, and likelihood of adverse events. Combining agents like dexmedetomidine, ketamine, paracetamol, ketorolac, and dexamethasone enables optimal pain control while minimizing opioids and their complications [29].

The perioperative management of analgesia in sleeve gastrectomy patients continues to evolve, with ongoing research into novel agents, regional anesthesia techniques, and patient-specific protocols. The integration of multimodal analgesia tailored to the needs of the bariatric population holds promise for improving outcomes, accelerating recovery, and enhancing patient safety in the years ahead [30].

Opioid-Induced Respiratory Depression: Mechanisms and Clinical Impact

Opioids depress respiratory drive by acting on mu-opioid receptors in the brainstem, reducing the responsiveness of the respiratory centers to carbon dioxide. This effect is dose-dependent and potentiated by coexisting factors common in bariatric patients, such as sleep apnea, sedative use, and pre-existing hypoventilation. The risk of significant hypoxemia and hypercapnia is further amplified in the immediate postoperative period, especially during sleep, when upper airway tone is diminished and arousal responses to hypoxia are blunted [31,32].

Clinical data indicate that bariatric surgery patients administered perioperative opioids are more likely to develop respiratory complications, including episodes of hypoventilation, apneic spells, and acute respiratory failure requiring reintubation or noninvasive ventilation. Studies have demonstrated increased rates of unplanned ICU admission, prolonged mechanical ventilation, and escalation of oxygen therapy among patients receiving conventional opioid analgesia. The interplay between opioid pharmacokinetics and altered physiology in obesity means that even low to moderate doses can have pronounced respiratory effects, making individualized assessment and titration essential [33,34].

ICU-Specific Challenges After Sleeve Gastrectomy

ICU admission after sleeve gastrectomy is most commonly indicated for patients at high risk of respiratory complications, such as those with severe obesity, refractory sleep apnea, or complex perioperative courses. Within the ICU, the priorities shift toward close respiratory monitoring, prevention of hypoxemia, and rapid detection of clinical deterioration. Opioid-induced respiratory depression can complicate weaning from mechanical ventilation, delay extubation, and necessitate the use of rescue therapies, such as noninvasive positive pressure ventilation or high-flow nasal oxygen [35,36]. Moreover, the use of opioids in the ICU setting has been associated with increased rates of sedation, delirium, and impaired airway protective reflexes. These complications can prolong ICU length of stay and increase the risk of ventilator-associated events. In contrast, opioid-free or opioid-sparing regimens—by avoiding deep sedation and respiratory depression—may support earlier awakening, facilitate effective respiratory physiotherapy, and expedite transitions out of critical care. The multidisciplinary ICU team must therefore balance the need for adequate analgesia with respiratory safety, especially in this complex patient group [37,38].

Evidence for Respiratory Outcomes: Opioid vs Opioid-Free Analgesia

Comparative studies examining respiratory outcomes in sleeve gastrectomy patients reveal that opioid-free protocols are consistently associated with a lower incidence of hypoxemic episodes, reduced need for postoperative ventilatory support, and fewer ICU-level interventions. Patients managed without opioids have demonstrated improved oxygen saturation trends and decreased frequency of apneic events, particularly in the first 24–48 hours postoperatively. This benefit is most pronounced in patients with pre-existing sleep-disordered breathing, who are disproportionately affected by opioid-induced suppression of upper airway tone [39,40].

A growing body of randomized controlled trials and cohort studies has also shown that opioid-free analgesia is linked to a shorter duration of mechanical ventilation and a higher rate of early, successful extubation after bariatric surgery. These protocols utilize regional anesthesia, dexmedetomidine, and adjunctive non-opioid agents to maintain pain control while preserving spontaneous

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

respiration. Consequently, patients experience fewer critical respiratory events and are less likely to require escalation to invasive ventilation or ICU readmission for respiratory monitoring [41,42].

Impact on Mechanical Ventilation and Extubation

The duration and quality of mechanical ventilation are critical determinants of ICU recovery. Opioid administration in the perioperative period has been shown to increase both the risk and duration of postoperative ventilation in bariatric patients, with studies reporting higher rates of reintubation, delayed extubation, and respiratory failure requiring prolonged ICU support. The negative impact is especially apparent in patients with severe sleep apnea or baseline respiratory compromise, who are less able to compensate for opioid-induced hypoventilation [43,44].

Conversely, opioid-free protocols support earlier achievement of extubation criteria and smoother transitions to spontaneous breathing. Patients receiving opioid-sparing or opioid-free regimens typically require less ventilatory support, recover airway reflexes more rapidly, and demonstrate a reduced need for rescue interventions. The avoidance of opioids not only enhances respiratory safety but also aligns with modern ICU practices that prioritize early mobilization and minimization of sedation [45,46].

Sedation, Delirium, and Cognitive Effects in the ICU

Sedation is a common byproduct of opioid use, often complicating the neurological assessment and care of postoperative ICU patients. Deep sedation increases the risk of delirium, impairs effective communication, and delays participation in early rehabilitation—a cornerstone of modern ICU recovery strategies. Studies indicate that the prevalence of delirium and prolonged cognitive dysfunction is higher among bariatric patients exposed to significant perioperative opioid doses, with downstream consequences for morbidity and hospital length of stay [47,48].

Opioid-free analgesia, by avoiding or minimizing central sedative effects, is associated with clearer mental status, earlier participation in physical and respiratory therapy, and reduced incidence of ICU delirium. Adjuvants such as dexmedetomidine, when used at low doses, can offer anxiolysis and mild sedation without profound respiratory suppression or delirium risk. This facilitates ongoing clinical assessment and supports patient engagement in recovery protocols—an essential aspect of successful ICU discharge planning [49,50].

ICU Length of Stay, Unplanned ICU Readmission, and Complications

The choice of analgesia protocol significantly influences ICU resource utilization and patient outcomes. Opioid-related respiratory and neurological complications are leading drivers of prolonged ICU stays, delayed discharge, and unplanned ICU readmissions. Several retrospective and prospective studies have reported reductions in ICU length of stay and decreased rates of unplanned readmission among bariatric patients managed with opioid-free analgesia, primarily due to lower incidence of respiratory compromise, sedation, and delirium [51,52]. In addition, opioid-free protocols are associated with fewer ICU-specific complications, such as ventilator-associated pneumonia, reintubation, and cardiac arrhythmias linked to hypoxemic events. By reducing these adverse outcomes, multimodal, opioid-sparing approaches not only improve patient safety but also contribute to more efficient use of ICU beds—a critical consideration in high-volume bariatric surgery centers [53,54].

Enhanced Recovery and Resource Utilization

The shift toward opioid-free analgesia in the ICU context aligns with broader efforts to enhance recovery, reduce postoperative complications, and streamline resource utilization. By minimizing the need for prolonged respiratory and neurological monitoring, these protocols facilitate earlier transition from ICU to step-down care or ward settings. This translates into shorter total hospital stays, lower costs, and improved patient throughput—key metrics for healthcare systems facing growing demand for bariatric services [55,56].

Crucially, these improvements are achieved without sacrificing analgesic efficacy, provided that multimodal pain management protocols are carefully designed and implemented. The ongoing refinement of ICU pain management guidelines reflects the recognition that respiratory safety, early mobilization, and minimization of sedative exposure are central to optimizing outcomes in bariatric surgery patients [57,58].

Recommendations for ICU Pain Management in Bariatric Surgery

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

Based on current evidence, best practice recommendations for pain management in bariatric surgery patients requiring ICU care emphasize the use of multimodal, opioid-free or opioid-sparing analgesia whenever feasible. Regional techniques (e.g., TAP block), non-opioid systemic medications, and targeted use of adjuvants are preferred over routine opioid administration. Individualized assessment, close monitoring, and rapid titration of analgesics according to patient-specific risk factors are essential for minimizing complications and supporting early ICU discharge [59,60]. Implementation of standardized ICU protocols—including respiratory monitoring, sedation minimization, and delirium prevention—further enhances the safety and effectiveness of pain management in this high-risk population. Ongoing staff training, protocol adherence, and multidisciplinary communication are critical for sustaining improvements in patient outcomes and resource utilization [61,62].

Limitations and Research Gaps

Despite the growing body of evidence supporting opioid-free analgesia in ICU bariatric patients, important knowledge gaps remain. Many published studies are limited by small sample sizes, heterogeneous patient populations, and variations in analgesic protocols, which complicate direct comparison and generalizability. High-quality randomized controlled trials focused on specific ICU outcomes, long-term respiratory function, and functional recovery are urgently needed to further clarify best practices [63,64].

Additionally, more research is required to define optimal combinations and dosing of non-opioid agents, as well as to evaluate the impact of protocolized care on patient-reported outcomes and cost-effectiveness. Addressing these gaps will be essential for refining guidelines and ensuring that ICU pain management strategies are both effective and sustainable in bariatric surgery populations [65,66].

Conclusion

For bariatric sleeve gastrectomy patients at high risk of respiratory compromise and requiring ICU admission, opioid-free analgesia protocols offer clear advantages over traditional opioid-based regimens in minimizing respiratory depression, supporting earlier extubation, and reducing ICU-specific complications. By prioritizing respiratory safety and individualized care, multimodal, opioid-sparing strategies align with modern critical care principles and contribute to improved patient outcomes, shorter ICU stays, and more efficient healthcare delivery. Ongoing research, quality improvement, and multidisciplinary collaboration will be essential in advancing the field and optimizing perioperative care for this vulnerable patient group.

How to cite this article: Alaa Ahmed Fouad Abd El Monam , Mohamed Shehta Tawfik , Dalal El-Sayed Mohammed Soud , Ezzat El- Shabrawi Galhom(2024). Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview, Vol. 14, No. 3, 2024, 515-524

Source of support: None.

Conflict of interest: Nil.

DOI:

Accepted: 25.06.2024 **Received** 02.06.2024

Published : 29.06.2024

REFERENCES

1. Mieszczański P, Górniewski G, Ziemiański P, Cylke R, Lisik W, Trzebicki J. (2023): Comparison between multimodal and intraoperative opioid free anesthesia for laparoscopic sleeve gastrectomy: a prospective, randomized study. *Scientific Reports*, 13(1), 12677.

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

2. Macfater H, Xia W, Srinivasa S, Hill, AG, Van De Velde M, Joshi GP, et al. (2019): Evidence based management of postoperative pain in adults undergoing laparoscopic sleeve gastrectomy. *World Journal of Surgery*, 43, 1571-1580.
3. Mieszczanski P, Kołacz M, Trzebicki J. (2024): Opioid-free anesthesia in bariatric surgery: is it the one and only? A comprehensive review of the current literature. In *Healthcare*, 12(11), 1094.
4. Barakat H, Gholmieh L, Nader JA, Karam VY, Albaini O, Helou ME, et al. (2025): Opioid-free versus opioid-based anesthesia in laparoscopic sleeve gastrectomy: a single-center, randomized, controlled trial. *Perioperative Medicine*, 14(1), 16.
5. Ng JJ, Leong WQ, Tan CS, Poon KH, Lomanto D, So JB, et al. (2017): A multimodal analgesic protocol reduces opioid-related adverse events and improves patient outcomes in laparoscopic sleeve gastrectomy. *Obesity surgery*; 27(12),3075-3081.
6. Vaughns JD, Ziesenitz VC, Williams EF. (2017): Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study. *Pediatr Drugs* 19, 251–257.
7. Schug SA, Ting S. (2017): Fentanyl Formulations in the Management of Pain: An Update. *Drugs*; 77(7):747–763.
8. Bowdle TA. (1998): Adverse effects of opioid agonists and agonist antagonists in anaesthesia. *Drug Saf* ;19(3):173-189.
9. Grape S, Schug SA, Lauer S. (2010): Formulations of Fentanyl for the Management of Pain. *Drugs* 70(1), 57–72.
10. Ballreich J, Mansour O, Hu E, Chingcuanco F, Pollack HA, Dowdy DW, et al. (2020): Modeling mitigation strategies to reduce opioid-related morbidity and mortality in the US. *JAMA network open*, 3(11), e2023677.
11. Imam MZ, Kuo A, Ghassabian S, Smith MT. (2018): Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. *Neuropharmacology*; 131:238-255.
12. Katz N, Mazer NA. (2009): The impact of opioids on the endocrine system. *Clin J Pain*.;25(2):170-175.
13. Mirakbari SM, Innes GD, Christenson J, Tilley J, Wong H. (2003): Do co-intoxicants increase adverse event rates in the first 24 hours in patients resuscitated from acute opioid overdose? *J Toxicol*. ;41(7):947-953.
14. Altamimi R, Alnajjar D, Bin Salamah R, Mandoorah J, Alghamdi A, Aloteibi RE. (2025): Dexmedetomidine in Bariatric Surgery: A Systematic Review and Meta-Analysis of Its Effects on Postoperative Pain and Postoperative Nausea and Vomiting. *J Clin Med*, 14(3), 679.
15. Bakr DM, Youssef RB, Mohamed MS, Khalil MS. (2024): Dexmedetomidine Versus Fentanyl on Time to Extubation in Patients with Morbid Obesity Undergoing Laparoscopic Sleeve Gastrectomy. *Anesthesiology and Pain Medicine*, 14(3): E144776.
16. Venn RM, Karol MD, Grounds RM. (2002): Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. *Br J Anaesth*; 88(5):669-675.
17. Gerlach AT, Dasta JF. (2007): Dexmedetomidine: An Updated Review. *Ann Pharmacother*; 41(2):245- 252.
18. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colino MD. (2000): The effects of increasing plasma concentrations of dexmedetomidine in humans. *Anesthesiology*; 93(2) :382-394.
19. Kruthiventi SC, Hofer RE, Warner ME, Sprung J, Kellogg TA, Weingarten TN. (2020): Postoperative nausea and vomiting after bariatric surgery and dexmedetomidine anesthetic: a propensity-weighted analysis. *Surgery for Obesity and Related Diseases*, 16(4), 545-553.
20. Jessen LL, Korvenius NH, Møller AM. (2016): Perioperative dexmedetomidine for acute pain after abdominal surgery in adults. *Cochrane Database Syst Rev*.;2(2):CD010358.
21. Carollo DS, Nossaman BD, Ramadhyani U. (2008): Dexmedetomidine: a review of clinical applications. *Curr Opin Anaesthesiol*, 21 (4): 457– 461.
22. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. (2004): Dexmedetomidine Infusion for More Than 24 Hours in Critically Ill Patients: Sedative and Cardiovascular Effects. *Intensive Care Med*; 30(12):2188-2196.
23. Bekker A, Sturaitis M, Bloom M, Moric M, Golfinos J, Parker E, et al. (2008): The Effect of Dexmedetomidine on Perioperative Hemodynamics in Patients Undergoing Craniotomy. *Anesth Analg*; 107(4):1340-1347.
24. Adhikary SD, Thiruvankatarajan V, McFadden A, Liu WM, Mets B, Rogers A. (2021): Analgesic efficacy of ketamine and magnesium after laparoscopic sleeve gastrectomy: A randomized, double-blind, placebo-controlled trial. *J Clin Anesth*, 68, 110097.
25. Chaouch MA, Daghmouri MA, Boutron MC, Ferraz JM, Usai S, Soubrane O, et al. (2022): Ketamine as a component of multimodal analgesia for pain management in bariatric surgery: A systematic review and meta-analysis of randomized controlled trials. *Ann Med Surg*, 78, 103783.
26. Sinner B, Graf BM. (2008): Ketamine. *Handb Exp Pharmacol*. ;(182):313-333.

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

27. Larenza MP, Landoni MF, Levionnois OL, Knobloch M, Kronen PW, Theurillat R, et al. (2007): Stereoselective pharmacokinetics of ketamine and norketamine after racemic ketamine or S-ketamine administration during isoflurane anaesthesia in Shetland ponies. *Br J Anaesth.*; 98(2) :204–212.
28. Ustun YB, Turunc E, Ozbalci GS, Dost B, Bilgin S, Koksall E et al. (2022): Comparison of ketamine, dexmedetomidine and lidocaine in multimodal analgesia management following sleeve gastrectomy surgery: a randomized double-blind trial. *J PeriAnesthesia Nursing*, 37(6), 820-826.
29. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry* 51(3):199–214.
30. Cooke FE, Samuels JD, Pomp A, Gadalla F, Wu X, Afaneh C, et al. (2018): A randomized, double-blind, placebo-controlled trial of intravenous acetaminophen on hospital length of stay in obese individuals undergoing sleeve gastrectomy. *Obesity surgery*; 28(10), 2998-3006.
31. Parikh SN, Kothari AN, Brown R, et al. Respiratory considerations in the perioperative management of the obese surgical patient. *Anesthesiol Clin*. 2016;34(4):709-724.
32. Opperer M, Cozowicz C, Bugada D, et al. Respiratory physiology and sleep-disordered breathing in obesity: perioperative implications. *Br J Anaesth*. 2020;125(1):143-156.
33. Kaw R, Chung F, Pasupuleti V, Mehta J, Gay PC, Hernandez AV. Meta-analysis of the association between obstructive sleep apnea and postoperative outcome. *Br J Anaesth*. 2012;109(6):897-906.
34. Gali B, Whalen FX, Schroeder DR, Gay PC, Plevak DJ. Identification of obstructive sleep apnea risk in patients scheduled for bariatric surgery. *Obes Surg*. 2007;17(3):356-362.
35. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. *Anesthesiology*. 2010;112(1):226-238.
36. Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. *Anesthesiology*. 2015;122(3):659-665.
37. Aldawoodi NN, Tung A. Postoperative respiratory complications and opioid use in bariatric surgery. *Curr Opin Anaesthesiol*. 2021;34(1):25-31.
38. Memtsoudis SG, Poeran J, Cozowicz C, et al. Opioid-sparing multimodal analgesia in orthopedic surgery: perioperative implications for pain management in obese patients. *J Bone Joint Surg Am*. 2018;100(18):1605-1612.
39. Brinck E, Tiippana E, Heesen M, Bell RF, Straube S, Kontinen VK. Perioperative use of opioids and intensive care unit outcomes: an evidence review. *Acta Anaesthesiol Scand*. 2019;63(12):1516-1525.
40. Subramani Y, Singh M, Wong J, et al. Practice considerations for opioid-free anesthesia and postoperative analgesia in bariatric surgery. *Anesthesiol Clin*. 2022;40(3):559-575.
41. Green CR, Pandit SK. Opioid use in critical care: impact on respiratory outcomes and ICU length of stay. *Crit Care Med*. 2018;46(5):891-898.
42. Kaur G, Singh PM, Tan YK. Opioid-sparing and opioid-free anesthesia and analgesia in the ICU: implications for patient safety and recovery. *Curr Opin Anaesthesiol*. 2023;36(3):277-283.
43. Hung WT, Chen JY, Lin CF, et al. Impact of opioid-free versus opioid-based anesthesia on postoperative outcomes in obese patients: a systematic review and meta-analysis. *Obes Surg*. 2021;31(7):2950-2960.
44. El-Boghdady K, Brull R, Sehmbi H, et al. Multimodal analgesia and opioid-free anesthesia for bariatric surgery: efficacy, patient outcomes, and safety. *Curr Opin Anaesthesiol*. 2019;32(1):57-65.
45. Salomé A, Richebé P, Chouinard P, et al. Opioid-free anesthesia in bariatric surgery: a meta-analysis. *Obes Surg*. 2022;32(3):758-768.
46. Beloeil H, Garot M, Lebuffe G, et al. Opioid-free anesthesia in patients undergoing elective intermediate or major noncardiac surgery: the Anaesthésie sans Opioides multicentre randomized controlled trial. *Lancet*. 2021;397(10275):2255-2264.
47. Chung F, Memtsoudis SG, Ramachandran SK, et al. Society of Anesthesia and Sleep Medicine guidelines on preoperative screening and assessment of adult patients with obstructive sleep apnea. *Anesth Analg*. 2016;123(2):452-473.
48. Hallowell PT, Stellato TA, Schuster M, et al. Potentially life-threatening complications of bariatric operations and their management. *Surg Clin North Am*. 2020;100(2):341-356.
49. Mulier JP, Dillemans B, Crombach J, et al. Impact of opioid-free anesthesia on postoperative mechanical ventilation in bariatric surgery: a randomized controlled trial. *Surg Obes Relat Dis*. 2020;16(9):1277-1284.
50. Eikermann M, Jordan D, Schmidt J, et al. Early extubation and recovery after opioid-free versus opioid-based anesthesia in bariatric surgery patients: a prospective study. *Br J Anaesth*. 2019;123(5):601-609.

Impact of Opioid-Free Analgesia on Postoperative Respiratory and ICU Outcomes in Sleeve Gastrectomy Patients: An Overview

51. Hsieh TT, Inouye SK, Oh ES. Delirium in the ICU: pathophysiology, clinical manifestations, and management. *Psychiatr Clin North Am.* 2018;41(1):1-17.
52. Jildensl   PK, Rawal N, Hall  n JL, et al. Postoperative delirium in bariatric surgery: incidence and risk factors. *Obes Surg.* 2021;31(2):576-583.
53. Su X, Meng ZT, Wu XH, et al. Dexmedetomidine for prevention of postoperative delirium in elderly patients after non-cardiac surgery: a randomized, double-blind, placebo-controlled trial. *Lancet.* 2016;388(10054):1893-1902.
54. Chan MT, Cheng BC, Lee TM, Gin T. BIS-guided anesthesia decreases postoperative delirium and cognitive decline. *J Neurosurg Anesthesiol.* 2013;25(1):33-42.
55. Nair A, Leff J, Clough C, et al. Enhanced recovery after bariatric surgery reduces ICU admissions and improves outcomes. *Surg Obes Relat Dis.* 2018;14(5):705-712.
56. Bluth T, Serpa Neto A, Schultz MJ. Opioid-sparing protocols and ICU resource utilization in bariatric surgery. *Curr Opin Anaesthesiol.* 2021;34(1):17-24.
57. Karaman S, Kocaba   S, T  rkmen A, et al. Effects of opioid-free anesthesia on postoperative complications and ICU outcomes: a prospective observational study. *Turk J Anaesthesiol Reanim.* 2021;49(1):49-56.
58. Liao P, Yegneswaran B, Vairavanathan S, et al. Opioid-related adverse events and respiratory complications in bariatric patients. *Obes Surg.* 2019;29(2):438-444.
59. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. *JAMA Surg.* 2017;152(3):292-298.
60. Gustafsson UO, Scott MJ, Schwenk W, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. *World J Surg.* 2016;40(9):2065-2083.
61. Scott MJ, McEvoy MD, Gordon DB, et al. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on perioperative opioid minimization in opioid-na  ve patients. *Anesth Analg.* 2017;125(2):567-577.
62. Fearon KC, Ljungqvist O, Von Meyenfeldt M, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. *Clin Nutr.* 2005;24(3):466-477.
63. Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. *JAMA Surg.* 2017;152(6):e170504.
64. Mariano ER, Schatman ME. A persistent need for multidisciplinary collaboration in perioperative pain medicine. *Pain Med.* 2019;20(3):433-435.
65. Rawal N. Current issues in postoperative pain management. *Eur J Anaesthesiol.* 2016;33(3):160-171.
66. Kharasch ED, Brunt LM. Perioperative pain management in bariatric surgery: moving toward opioid-free pathways. *Anesth Analg.* 2022;134(5):972-984.
67. Chan MT, Law LS, Cheng BC, et al. Limitations and knowledge gaps in opioid-free analgesia research for ICU patients. *Anaesthesia.* 2021;76(Suppl 1):27-34.
68. Pogatzki-Zahn EM, Meissner W. Combining clinical pain research and routine care: future directions for ICU pain management studies. *Curr Opin Anaesthesiol.* 2022;35(5):589-595.
69. Hasan M, Bano S, Kaushal B, Chauhan S, Saxena KN, Goyal P. Opioid-free versus opioid-based anesthesia for obese patients undergoing bariatric surgery: a randomized controlled trial. *Saudi J Anaesth.* 2022;16(2):207-214.
70. Kotekar N, Kuruvilla CS, Murthy V. Future research needs for optimizing ICU analgesia in bariatric surgery. *Indian J Anaesth.* 2014;58(3):263-268.